AXSOME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
AXSOME THERAPEUTICS, INC. (AXSM) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $1.13 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.13M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $765.63K.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $919.11K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $546.12K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $765.63K 10-Q · filed 2026-05-04 |
| 2025-12-31 | $919.11K 10-K · filed 2026-02-23 |
| 2025-09-30 | $546.12K 10-Q · filed 2025-11-03 |
| 2025-06-30 | $450.57K 10-Q · filed 2025-08-04 |
| 2025-03-31 | $565.50K 10-Q · filed 2025-05-05 |
| 2024-12-31 | $321.48K 10-K · filed 2025-02-18 |
| 2024-09-30 | $369.49K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $314.48K 10-Q · filed 2024-08-05 |
| 2024-03-31 | $318.27M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $323.16K 10-K · filed 2024-02-23 |
| 2023-09-30 | $244.07K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $264.78K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $161.92K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $300.65M 10-K · filed 2023-02-28 |
| 2022-09-30 | $117.06M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $95.08M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $106.19M 10-Q · filed 2022-05-02 |
| 2021-12-31 | $80.65M 10-K · filed 2022-03-01 |
| 2021-09-30 | $184.60M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $186.30M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $248.41M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $243.56M 10-K · filed 2021-03-01 |
| 2020-09-30 | $213.79M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $259.89M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $171.74M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $322.23M 10-K · filed 2020-03-12 |
| 2019-09-30 | $36.93M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $56.37M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $21.66M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $216.65K 10-K · filed 2019-03-15 |
| 2018-09-30 | $1.13M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $919.84K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $463.71K 10-Q · filed 2018-05-08 |
| 2017-12-31 | $2.39M 10-K · filed 2018-03-07 |
| 2017-09-30 | $2.35M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $2.29M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.12M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $2.99M 10-K · filed 2017-03-07 |
| 2016-09-30 | $4.00M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $3.23M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $4.65M 10-Q/A · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |